Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DMT1OZ6)

Drug Name

MK-2206 Drug Info

Synonyms

MK-2206; 1032349-93-1; UNII-51HZG6MP1K; MK 2206; 51HZG6MP1K; CHEMBL1079175; CHEBI:67271; NCGC00186465-01; 8-[4-(1-aminocyclobutyl)phenyl]-9-phenyl-2H-[1,2,4]triazolo[3,4-f][1,6]naphthyridin-3-one; DSSTox_RID_83143; DSSTox_CID_28874; 8-[4-(1-aminocyclobutyl)phenyl]-9-phenyl-1,2,4-Triazolo[3,4-f][1,6]naphthyridin-3(2H)-one; DSSTox_GSID_48948; 8-[4-(1-aminocyclobutyl)phenyl]-9-phenyl[1,2,4]triazolo[3,4-f][1,6]naphthyridin-3(2H)-one; 1,2,4-Triazolo[3,4-f][1,6]naphthyridin-3(2H)-one, 8-[4-(1-aminocyclobutyl)phenyl]-9-phenyl-;

Indication

Disease Entry	ICD 11	Status	REF
Rectal adenocarcinoma	2B92	Phase 2	[1]
Nasopharyngeal carcinoma	2B6B	Investigative	[2]

Cross-matching ID

PubChem CID: 24964624
ChEBI ID: CHEBI:67271
CAS Number: CAS 1032349-93-1
TTD Drug ID: DMT1OZ6

Molecule(s) Related to This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
E2 ubiquitin-conjugating enzyme T (UBE2T)	TT0A1R8	UBE2T_HUMAN	Inhibitor	[2]
RAC-gamma serine/threonine-protein kinase (AKT3)	TTAZ05C	AKT3_HUMAN	Modulator	[3]

------------------------------------------------------------------------------------

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule	Molecule Type	Gene Name	Liver	Colon	Kidney	Small Intestine
RAC-gamma serine/threonine-protein kinase (AKT3)	DTT	AKT3	5.229	6.298	5.675	5.15

Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease

Rectal adenocarcinoma

ICD Disease Classification

2B92

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
RAC-gamma serine/threonine-protein kinase (AKT3)	DTT	AKT3	6.79E-01	-0.02	-0.08

Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7945).
2	UBE2T promotes nasopharyngeal carcinoma cell proliferation, invasion, and metastasis by activating the AKT/GSK3/-catenin pathway.Oncotarget. 2016 Mar 22;7(12):15161-72.
3	First-in-man clinical trial of the oral pan-AKT inhibitor MK-2206 in patients with advanced solid tumors.J Clin Oncol.2011 Dec 10;29(35):4688-95.